News Release 

Two studies support key role for immune system in shaping SARS-CoV-2 evolution

New findings and novel technology could inform COVID-19 treatment and vaccine-development efforts

PLOS

Research News

IMAGE

IMAGE: Colorized scanning electron micrograph of an apoptotic cell (pink) heavily infected with SARS-COV-2 virus particles (green), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF)... view more 

Credit: National Institute of Allergy and Infectious Diseases/NIH, 2020

Two studies published in the open-access journal PLOS Pathogens provide new evidence supporting an important role for the immune system in shaping the evolution of SARS-CoV-2, the virus that causes COVID-19. These findings--and the novel technology behind them--improve understanding of how new SARS-CoV-2 strains arise, which could help guide treatment and vaccination efforts.

For the first study, Rachel Eguia of Fred Hutchinson Cancer Research Center in Seattle, Washington, and colleagues sought to better understand SARS-CoV-2 by investigating a closely related virus that has circulated widely for a far longer period of time: the common-cold virus 229E.

229E and SARS-CoV-2 are both in the coronavirus family, which features a "spike protein" that enables infection of human cells. A person who is infected with 229E develops an immune response against the spike protein that protects them from reinfection, but only for a few years. Whether reinfection then occurs because the immune response wears off or because 229E evolves to escape it has been unclear.

Eguia and colleagues addressed this question by testing the activity of serum samples collected from patients in the 1980s-90s against spike proteins from both old 229E strains and strains that evolved later on. They found that the old spike proteins were vulnerable to the older sera. However, modern spike proteins were able to evade older sera while remaining vulnerable to sera from modern patients.

This analysis suggests that modern strains of 229E have accumulated spike protein mutations that enable them to evade older sera. These findings raise the possibility that SARS-CoV-2 and other coronaviruses could undergo similar evolution, and that COVID-19 vaccines may require periodic updates to remain effective against new strains.

The authors add, "The human common-cold coronavirus evolves over the span of years to decades to erode neutralization by human polyclonal serum antibodies. This work suggests that human coronaviruses undergo significant antigenic evolution that may contribute to eventual re-infections."

For the second study, Sung Hee Ko of the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, and colleagues developed new technology for genetic sequencing of the SARS-CoV-2 spike protein, enabling detection of multiple SARS-CoV-2 strains that may be present at the same time within a single infected patient.

Previous studies have used standard sequencing methods to produce a single genetic sequence from an individual patient, obscuring the potential presence of multiple SARS-CoV-2 strains. By contrast, the new technology highlights virus diversity within each patient and enables tracking of the evolution of new SARS-CoV-2 strains during acute infection.

Indeed, when the researchers applied the new method to human respiratory samples, they found new SARS-CoV-2 variants arising within the same patient over the course of acute infection. The precise mutations in these variants suggest that they arose in response to selective pressure from the immune system.

Future application of the new technology could improve understanding of how the evolution of new SARS-CoV-2 variants within a single patient impacts their outcomes. The findings also suggest that patients might see greater benefits from early treatment with antiviral drugs capable of targeting multiple strains, than from delayed treatment with a single antiviral drug.

The authors add, "We used new technology to show that coronavirus variants with mutated spike proteins can arise early in the course of infection. Our results suggest more virus evolution in each person than previously thought, with potential implications for clinical outcomes and for the emergence of transmissible variant strains."

Together, these two studies deepen understanding of how new SARS-CoV-2 strains arise in response to immune system activity, potentially paving the way for additional research and improved treatment.

###

Peer-reviewed; Experimental study; People; Cells

In your coverage, please use these URLs to provide access to the freely available articles in PLOS Pathogens: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009431 http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009453

Citation (Paper 1): Ko SH, Bayat Mokhtari E, Mudvari P, Stein S, Stringham CD, Wagner D, et al. (2021) High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. PLoS Pathog 17(4): e1009431. https://doi.org/10.1371/journal.ppat.1009431

Citation (Paper 2): Eguia RT, Crawford KHD, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger AL, Englund JA, et al. (2021) A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog 17(4): e1009453. https://doi.org/10.1371/journal.ppat.1009453

Funding (Paper 1): Funding was provided by the Intramural Research Program of the U.S. National Institutes of Health (project AI005157-01, E.A.B). M.J.R-B. is supported by NIGMS Postdoctoral Research Associate Training Program (1FI2GM137804-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Funding (Paper 2): This work was supported by the following grants from the National Institute of Allergy and Infectious Disease of the National Institutes of Health (https://www.niaid.nih.gov/): R01AI127893 (to JDB), R01AI141707 (to JDB), F30AI149928 (to KDC). JDB is an Investigator of the Howard Hughes Medical Institute (HHMI, https://www.hhmi.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests (Paper 1): The authors declare no competing interests.

Competing Interests (Paper 2): I have read the journal's policy and the authors of this manuscript have the following competing interests: MJB has consulted for Moderna and Vir Biotechnologies, and received research funding from Regeneron and Vir Biotechnologies. JAE has consulted for Meissa Vaccines and Sanofi Pasteur, and received research funding from Merck, GlaxoSmithKline, Pfizer, and AstraZeneca. The other authors declare no competing interests.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.